JP2016502995A5 - - Google Patents

Download PDF

Info

Publication number
JP2016502995A5
JP2016502995A5 JP2015547071A JP2015547071A JP2016502995A5 JP 2016502995 A5 JP2016502995 A5 JP 2016502995A5 JP 2015547071 A JP2015547071 A JP 2015547071A JP 2015547071 A JP2015547071 A JP 2015547071A JP 2016502995 A5 JP2016502995 A5 JP 2016502995A5
Authority
JP
Japan
Prior art keywords
vaccine composition
vaccine
intranasal
composition according
glycerol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015547071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502995A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/076905 external-priority patent/WO2014095866A1/en
Publication of JP2016502995A publication Critical patent/JP2016502995A/ja
Publication of JP2016502995A5 publication Critical patent/JP2016502995A5/ja
Ceased legal-status Critical Current

Links

JP2015547071A 2012-12-17 2013-12-17 鼻腔内予防接種投薬レジメン Ceased JP2016502995A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201270788 2012-12-17
DKPA201270788 2012-12-17
PCT/EP2013/076905 WO2014095866A1 (en) 2012-12-17 2013-12-17 Intranasal vaccination dosage regimen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018135426A Division JP2018172434A (ja) 2012-12-17 2018-07-19 鼻腔内予防接種投薬レジメン

Publications (2)

Publication Number Publication Date
JP2016502995A JP2016502995A (ja) 2016-02-01
JP2016502995A5 true JP2016502995A5 (enExample) 2016-12-01

Family

ID=49880734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015547071A Ceased JP2016502995A (ja) 2012-12-17 2013-12-17 鼻腔内予防接種投薬レジメン
JP2018135426A Pending JP2018172434A (ja) 2012-12-17 2018-07-19 鼻腔内予防接種投薬レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018135426A Pending JP2018172434A (ja) 2012-12-17 2018-07-19 鼻腔内予防接種投薬レジメン

Country Status (7)

Country Link
US (1) US9700614B2 (enExample)
EP (1) EP2931309A1 (enExample)
JP (2) JP2016502995A (enExample)
AU (1) AU2013361781B2 (enExample)
HK (1) HK1215546A1 (enExample)
PH (1) PH12015501459A1 (enExample)
WO (1) WO2014095866A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
US12589149B2 (en) 2019-03-20 2026-03-31 Advagene Biopharma Co., Ltd. Method of modulating mucosal immunogenicity
EP4565268A1 (en) * 2022-08-02 2025-06-11 Yale University Compositions, kits, and methods of immunizing against viral infections

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1187629T3 (da) * 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
ES2399386T3 (es) * 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
US7964200B2 (en) 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
EP1945253A2 (en) * 2005-11-04 2008-07-23 Novartis Vaccines and Diagnostics S.r.l. Adminstration routes for priming/boosting with influenza vaccines
US8535683B2 (en) 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
US20100143393A1 (en) 2006-05-11 2010-06-10 Gale Smith Novel influenza m2 vaccines
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
US8658180B2 (en) 2008-08-15 2014-02-25 Mark A. Miller Vaccines against influenza virus
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
CN103154021A (zh) 2010-08-16 2013-06-12 威斯特解剖及生物研究所 通用甲型流感疫苗
US20130243817A1 (en) 2010-09-30 2013-09-19 Eurocine Vaccines Ab Vaccine compositions

Similar Documents

Publication Publication Date Title
WO2013006842A3 (en) Self-replicating rna prime - protein boost vaccines
EP4056198A3 (en) Outer membrane vesicles
WO2013143683A8 (en) Rna formulation for immunotherapy
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
WO2013177214A3 (en) Epitope focusing by variable effective antigen surface concentration
EP4494650A3 (en) Vaccine compositions having improved stability and immunogenicity
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
MX392812B (es) Lipidos cationicos de trialquilo y metodos de uso de los mismos.
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
EA201790239A1 (ru) Молекула-носитель для антигенов
PE20140845A1 (es) Formulaciones parenterales de vacunas contra los norovirus
GEP20166457B (en) Low-oil pharmaceutical emulsion compositions comprising progestogen
EP2897640A4 (en) HEPATITIS B VIRUS CORE PROTEIN AND SURFACE ANTIBODY PROTEIN AND VACCINE THEREWITH
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
FI3656395T3 (fi) Menetelmiä ja koostumuksia suojaavan immuniteetin aikaansaamiseksi filovirusinfektiota vastaan
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
WO2010129947A3 (en) Alpha thymosin peptides as vaccine enhancers
EP2762153A3 (en) Vaccine composition for mucosal administration
WO2015149016A3 (en) Breast and ovarian cancer vaccines
JP2016531853A5 (enExample)
MX358507B (es) Antigenos vacunales quimericos contra el virus de la hepatitis c.